Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
Teva
Queensland Health
Citi
Federal Trade Commission
Chinese Patent Office
Express Scripts
Merck
US Department of Justice

Generated: February 21, 2018

DrugPatentWatch Database Preview

RISPERDAL Drug Profile

« Back to Dashboard

When do Risperdal patents expire, and what generic alternatives are available?

Risperdal is a drug marketed by Janssen Pharms and is included in four NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in RISPERDAL is risperidone. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.
Drug patent expirations by year for RISPERDAL
Pharmacology for RISPERDAL
Medical Subject Heading (MeSH) Categories for RISPERDAL

US Patents and Regulatory Information for RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-003 Oct 29, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RISPERDAL risperidone SOLUTION;ORAL 020588-001 Jun 10, 1996 AA RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-001 Oct 29, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-002 Oct 29, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-008 May 10, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-003 Apr 2, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-004 Dec 29, 1993 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-001 Oct 29, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-007 Jan 27, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-001 Oct 29, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-008 May 10, 1999 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-003 Apr 2, 2003 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-004 Dec 23, 2004 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone SOLUTION;ORAL 020588-001 Jun 10, 1996 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-005 Dec 29, 1993 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone SOLUTION;ORAL 020588-001 Jun 10, 1996 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-002 Apr 2, 2003 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-005 Dec 23, 2004 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET;ORAL 020272-003 Dec 29, 1993 ➤ Sign Up ➤ Sign Up
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-004 Dec 23, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RISPERDAL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 0.25 mg ➤ Subscribe 4/11/2005
➤ Subscribe Orally Disintegrating Tablets 3 mg and 4 mg ➤ Subscribe 3/23/2005

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Boehringer Ingelheim
Cipla
Argus Health
Baxter
Teva
Julphar
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot